Risk stratification of severe infections after remission induction therapy in idiopathic inflammatory myopathy: a multicentre MYKO study
Authors' conclusion
This model, which consists of CRP ≥ 0.8 mg/dl, SP-D ≥ 96.2 ng/ml, is useful for clinical risk stratification of SI after remission induction therapy in IIM.
Study context
- Population
- Patients diagnosed with idiopathic inflammatory myopathy (IIM) between 1991 and 2024 from three Japanese centres participating in the MYKO cohort, after remission induction therapypatients with IIM
- Participants
- 349 patientsEvents: 14.6%
- Predictors
- Number of risk factors, defined as CRP ≥ 0.8 mg/dl and SP-D ≥ 96.2 ng/ml
- Predicted outcome
- severe infections (SIs) after remission induction therapy (infection requiring i.v. antibiotics or hospitalization)
Methodological detailsthree Japanese centres, multicentre Idiopathic Inflammatory Myopathy and Anti-synthetase Syndrome (MYKO) cohort, multivariate logistic regression analysis
- Three Japanese centres
- Multicentre Idiopathic Inflammatory Myopathy and Anti-synthetase Syndrome (MYKO) cohort
- Multivariate logistic regression analysis
Model performance
As reported in the abstract
10-year
- The 10-year SI rate was significantly different among patients with IIM stratified by the number of risk factors
Further findings
Baseline levels, SI vs non-SI
- Significantly lower baseline albumin levels in patients who developed SI
- Significantly higher baseline CRP, lactate dehydrogenase and surfactant protein (SP-D) levels in patients who developed SI
Independent association with SI (multivariate logistic regression)
- Elevated CRP and SP-D levels were independently associated with SI
Serum CRP and SP-D levels after immunosuppressive therapy · 2-year period after immunosuppressive therapy
- Serum CRP levels remained significantly higher in the SI group than in the non-SI group
- Serum SP-D levels tended to be higher in the SI group
Original publication
Risk stratification of severe infections after remission induction therapy in idiopathic inflammatory myopathy: a multicentre MYKO study. Rheumatology (Oxford). Published 28 October 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →